Skip to main content
CTE ResearchWashington University· 7 min read· in Health

Blood Biomarker Shows Promise for Diagnosing Advanced CTE in Living Patients

Researchers at Washington University have identified a blood biomarker that detects advanced chronic traumatic encephalopathy (CTE). The tau protein fragment could eventually enable clinical trials for CTE treatments and monitoring for at-risk athletes and veterans.

By Jun Zhao

Share this story

Listen

Medical researchers have identified a blood biomarker capable of detecting advanced chronic traumatic encephalopathy (CTE), offering a potential pathway to diagnose the degenerative brain disease in living patients. A team at Washington University School of Medicine in St. Louis found that a specific tau protein fragment, eMTBR-tau243, is elevated in the blood of individuals with advanced CTE.[2][3]

The discovery marks a significant step toward monitoring athletes and military veterans who have sustained repeated head trauma. Currently, CTE can only be confirmed by examining brain tissue after a patient has died. Doctors attempting to diagnose the condition in living patients must rely on evaluating clinical symptoms, such as severe mood swings and progressive memory loss.[2]

The clinical presentation of CTE often begins 10 to 20 years after an individual has retired from contact sports or military combat. Early symptoms typically include subtle changes in mood and behavior, such as increased impulsivity, depression, and uncharacteristic aggression. As the disease advances, patients frequently experience severe cognitive impairment and progressive dementia.[2]

Because these symptoms closely mirror those of Alzheimer's disease and standard age-related cognitive decline, clinical diagnoses remain speculative. Physicians can classify a living patient as having Traumatic Encephalopathy Syndrome, the clinical manifestation of the disease. However, they cannot definitively confirm the underlying CTE pathology without physically examining the brain tissue.[2]

This diagnostic limitation has severely hindered the development of targeted therapies. Because physicians cannot definitively identify living patients with CTE, researchers are unable to enroll verified candidates into clinical trials. Pharmaceutical companies are actively developing potential treatments, but they lack a biological mechanism to rapidly evaluate whether an experimental drug is working.[3]

The Washington University team originally studied the eMTBR-tau243 fragment to track toxic protein clumps in Alzheimer's disease. While analyzing samples from 80 people with autopsy-confirmed brain diseases, they discovered a surprising outlier. One patient exhibited unexpectedly high levels of the biomarker despite autopsy records showing no signs of Alzheimer's disease.[2][3]

The study analyzed samples from 229 participants to test the biomarker's specificity.

Combing through the clinical and pathological records, the researchers found that this specific patient had advanced CTE. Recognizing that the tau protein clumps in Alzheimer's and CTE share similar structural characteristics, the team pivoted. They began investigating whether the blood marker could consistently identify the trauma-induced disease in other patients.[3]

The mechanism of tau proteins

Tau proteins normally serve a vital function in the brain, helping to support the internal microtubule structure of healthy nerve cells. However, in certain neurodegenerative conditions, these proteins become abnormal and detach from the microtubules. They subsequently tangle together inside the neurons, forming toxic clumps that disrupt cellular communication.[3]

Tau proteins exist in two main forms within the human brain, known as 3-repeat and 4-repeat tau. In some specific tau-related diseases, known as tauopathies, only one of these forms accumulates into clumps. In both Alzheimer's disease and CTE, however, both forms of the tau protein tangle together, which is why the eMTBR-tau243 fragment is elevated in both conditions.[3]

To rigorously test the biomarker's specificity, the Washington University researchers collaborated with scientists at the University of California, San Francisco. Together, they analyzed samples from 229 participants drawn from several biorepositories. This extensive screening process utilized a highly sensitive mass spectrometry assay developed at the WashU Medicine Tracy Family SILQ Center.[3]

Diagnostic limitations and overlap

The researchers acquired stored blood samples from 11 individuals whose CTE had been definitively confirmed at autopsy, comparing them against the remaining 218 samples. When they tested these 11 samples, they found that levels of eMTBR-tau243 were significantly higher than in healthy volunteers. Furthermore, the concentration of the biomarker in the blood rose in tandem with the severity of the brain disease.[1][3]

While the blood test distinguished patients with advanced CTE from healthy individuals with high accuracy, it failed to reliably identify early-stage disease. The concentration of eMTBR-tau243 in CTE patients was also substantially lower than the levels typically observed in patients with Alzheimer's disease.[2][3]

Illustration: The research team utilized a highly sensitive mass spectrometry assay to detect the tau protein fragment.

Because the biomarker is elevated in both conditions, and because Alzheimer's frequently co-occurs with CTE in older adults, the test cannot serve as a standalone diagnostic tool. "This is not going to be a standalone biomarker," said Chihiro Sato, an assistant professor of neurology at WashU Medicine.[3]

"But if someone has a history of repeated head injury, tests negative for Alzheimer's, and this biomarker comes up, it might be CTE," Sato explained. This layered diagnostic approach could eventually allow clinicians to rule out other conditions before attributing cognitive decline to previous head trauma.[3]

Independent neuropathologists emphasize the need for extensive follow-up research before the test can enter routine clinical use. Dr. Rudolph Castellani, a neuropathologist at Northwestern University who was not involved in the study, cautioned that the findings remain highly preliminary. He noted that abnormal tau is present in several overlapping brain diseases.[2]

The small sample size of 11 CTE patients means that far larger studies are required to validate the connection. Researchers must ensure the biomarker's reliability across broader populations and verify that it does not produce false positives in patients with other neurodegenerative conditions.[2]

Unlocking future clinical trials

Despite the caveats, the identification of a measurable blood marker provides a critical foundation for future CTE research. "Many pharmaceutical companies are developing therapies that could potentially treat CTE, but we do not have biomarkers to identify the disease and to rapidly see if a treatment is working," said Kanta Horie.[3]

Horie, a research associate professor of neurology at WashU Medicine, noted that the findings broaden therapeutic opportunities beyond Alzheimer's disease. "We are potentially opening a new door for diagnosing and treating CTE in living patients," Horie said following the study's publication on November 13, 2026, in the journal JAMA.[1][3]

Washington University has already licensed the technology to measure eMTBR-tau243 in blood to C2N Diagnostics. The WashU startup previously developed an FDA-cleared blood test to aid in diagnosing Alzheimer's disease, providing an established commercial pathway for the new assay once it undergoes rigorous clinical validation.[3]

Bringing a new diagnostic biomarker from the laboratory to the clinic requires navigating a complex regulatory landscape. C2N Diagnostics will need to conduct multi-center clinical trials to prove that the eMTBR-tau243 assay can consistently identify CTE pathology across diverse demographic groups and varying levels of traumatic exposure.[3]

If these trials are successful, the company would then submit the data to the Food and Drug Administration for formal clearance. This regulatory process ensures that the test's sensitivity and specificity meet strict clinical standards, preventing doctors from delivering false positive diagnoses that could unnecessarily alarm patients.[3]

Broader implications for contact sports

A reliable diagnostic test would fundamentally alter how professional sports leagues manage the long-term health of their athletes. CTE is especially prevalent in collision sports; a recent study of nearly 400 deceased National Football League players found evidence of the disease in 93.5 percent of the donated brains.[1]

CTE remains highly prevalent among athletes exposed to repeated head trauma in collision sports.

More than 350 former NFL players have been diagnosed with CTE post-mortem, including Hall of Fame center Mike Webster, who died in 2002 at age 50, and linebacker Junior Seau, who died in 2012 at age 43. The crisis extends to global sports, with living former rugby union players currently pursuing legal action over head trauma.[1]

The implications extend far beyond professional athletics, offering hope to military veterans who have been exposed to blast waves and repeated concussive forces during combat deployments. The Department of Veterans Affairs currently manages thousands of patients presenting with traumatic brain injuries, many of whom face an uncertain neurological future.[2]

If larger trials confirm the initial results, clinicians could eventually use the blood test to proactively monitor high-risk individuals. Rather than waiting for severe cognitive decline to manifest, doctors could track the biological progression of the disease in boxers, combat veterans, and retired football players.[1]

Illustration: A reliable blood test could fundamentally alter how professional sports leagues manage the long-term health of their athletes.

The next verifiable checkpoint for the research team involves testing the biomarker in a significantly larger and more diverse cohort of patients. Until those results are published, eMTBR-tau243 remains a promising research tool rather than a definitive clinical answer for the thousands of athletes living with the threat of CTE.[2]

Key points

  • A blood test measuring the tau protein fragment eMTBR-tau243 successfully identified advanced CTE in a small cohort of 11 autopsy-confirmed cases.
  • CTE is a degenerative brain disease linked to repeated head trauma, currently diagnosable only by examining brain tissue after death.
  • The biomarker cannot reliably detect early-stage CTE and is also elevated in Alzheimer's disease, meaning it cannot be used as a standalone diagnostic tool.
  • If validated in larger studies, the test could allow doctors to monitor at-risk individuals and facilitate clinical trials for CTE treatments.

What we don’t know

  • Whether the eMTBR-tau243 biomarker can be refined to reliably detect early-stage CTE before severe cognitive symptoms appear.
  • How the blood test will perform in a significantly larger and more diverse patient population during upcoming clinical trials.
  • When a clinically validated and FDA-cleared CTE blood test might become widely available to the public.
  • Because this is a newly published study, independent media coverage remains thin, leaving it unclear how the broader neurological community will receive the findings.
Medical Researchers 60%Independent Neuropathologists 40%
Medical Researchers
Optimistic that the biomarker provides a necessary biological foothold to begin clinical trials for CTE treatments.
Independent Neuropathologists
Caution that the findings are highly preliminary and complicated by the biomarker's overlap with other neurodegenerative diseases.

Perspectives this story doesn't cover

  • Former contact sports athletes
  • Military veterans with traumatic brain injuries

Sources

Source coverage

3 outlets

2 viewpoints surfaced

Medical Researchers 60%Independent Neuropathologists 40%
  1. [1]The GuardianMedical Researchers

    Scientists find blood biomarker that opens door to CTE diagnosis in living patients

    Read on The Guardian →
  2. [2]AP NewsIndependent Neuropathologists

    Preliminary study finds a clue in the quest to help diagnose CTE in the living

    Read on AP News →
  3. [3]WashU MedicineMedical Researchers

    Progress toward a blood test for CTE

    Read on WashU Medicine →
Listen

Comments

Stay informed

Every angle. Every day.

Get Health stories with full source coverage and perspective breakdowns, free every day.